Company intelligence / Profile preview

Welichem Biotech

Burnaby, British Columbia, Canadapitchbook.com ↗

Ownership: Private
Development stage: Commercial

Overview

Welichem Biotech developed a pipeline of small molecule therapeutics for autoimmune/inflammatory diseases and cancer using its proprietary Symbiochem platform. Its lead candidate WBI-1001 showed promising safety and efficacy in Phase 1/2 trials for psoriasis and atopic dermatitis. The rights to WBI-1001 were acquired by Stiefel/GSK in 2012–2014 for global development outside China/Taiwan/Macau/Hong Kong. Other programs remained preclinical or early clinical.

Therapeutic areas: OncologyDermatologyImmunology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

tapinarof

Commercial

Indications: Psoriasis, Atopic dermatitis

Partnerships

Stiefel/GSKShenzhen Celestial Pharmaceuticals Ltd.Beijing Wenfeng Tianji Pharmaceuticals Co. Ltd.

Beyond the preview

Go deeper on Welichem Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Welichem Biotech.

Explore the full profile